

Response to Restriction Requirement

Attorney Docket R0127B-REG

CLAIM LISTING:

1-22. (Canceled)

23. (Previously presented) A method of treatment of a patient having a condition associated with the level of CLCA1, comprising contacting cells of said patient with a nucleic acid molecule that down regulates expression of CLCA1 (Chloride Channel Calcium Activated) gene under conditions suitable for said treatment.

24. (Previously presented) The method of claim 23 further comprising the use of one or more therapies under conditions suitable for said treatment.

25. (Previously presented) A method of cleaving RNA of a CLCA1 gene, comprising contacting an enzymatic nucleic acid molecule that down regulates expression of CLCA1 (Chloride Channel Calcium Activated) gene with said RNA under conditions suitable for the cleavage of said RNA.

26. (Previously presented) The method of claim 25, wherein said cleavage is carried out in the presence of a divalent cation.

27. (Previously presented) The method of claim 26, wherein said divalent cation is Mg^{2+} .

28-44 (canceled)

45. (Previously presented) A method for treatment of chronic obstructive pulmonary disease comprising the step of administering to a patient a nucleic acid molecule that down regulates expression of CLCA1 (Chloride Channel Calcium Activated) gene under conditions suitable for said treatment.

46. (Previously presented) A method for treatment of cystic fibrosis comprising the step of administering to a patient a nucleic acid molecule that down regulates expression of CLCA1 (Chloride Channel Calcium Activated) gene under conditions suitable for said treatment.

GREENC3:128085v1

2

Response to Restriction Requirement

Attorney Docket R0127B-REG

47-48. (canceled)

49. (Previously presented) The method of claims 45 or 46, wherein said method further comprises administering to said patient the nucleic acid molecule in conjunction with one or more other therapies.

50. (Previously presented) The method of claim 49, wherein said other therapies are therapies selected from the group consisting of oxygen therapy, bronchodilators, corticosteroids, antibacterials, vaccinations, acetylcystein, mucokinetic agents, and DNase (Pulmozyme) treatments.

51-60. (canceled)

61. (Previously presented) A method of reducing CLCA1 activity in a cell, comprising the step of contacting said cell with an enzymatic nucleic acid molecule, under conditions suitable for said reduction of CLCA1 activity, wherein said enzymatic nucleic acid molecule comprises a binding arm having a sequence complementary to any sequences having SEQ ID NOs:1-2189 and 5399-5416.

62. (Previously presented) A method of reducing CLCA1 activity in a cell, comprising the step of contacting said cell with an enzymatic nucleic acid molecule, under conditions suitable for said reduction of CLCA1 activity, wherein said enzymatic nucleic acid molecule comprises a binding arm having a sequence complementary to any sequences having SEQ ID NOs:2190-5398 and 5425-5434.

63. (Previously presented) The method of claim 61, wherein said enzymatic nucleic acid molecule is in a hammerhead (HH) motif.

64. (Previously presented) The method of claim 62, wherein said enzymatic nucleic acid molecule is in a hammerhead (HH) motif.

Response to Restriction Requirement

Attorney Docket R0127B-REG

65. (Previously presented) The method of claim 61, wherein said enzymatic nucleic acid molecule is in a hairpin, hepatitis Delta virus, group 1 intron, VS nucleic acid, amberzyme, zinzyme or RNase P nucleic acid motif.

66. (Previously presented) The method of claim 62, wherein said enzymatic nucleic acid molecule is in a hairpin, hepatitis Delta virus, group 1 intron, VS nucleic acid, amberzyme, zinzyme or RNase P nucleic acid motif.

67. (Previously presented) The method of claim 61, wherein said enzymatic nucleic acid molecule is in an Inozyme motif.

68. (Previously presented) The method of claim 62, wherein said enzymatic nucleic acid molecule is in an Inozyme motif.

69. (Previously presented) The method of claim 61, wherein said enzymatic nucleic acid molecule is in a G-cleaver motif.

70. (Previously presented) The method of claim 62, wherein said enzymatic nucleic acid molecule is in a G-cleaver motif.

71. (Previously presented) The method of claim 61, wherein said enzymatic nucleic acid molecule is a DNAzyme.

72. (Previously presented) The method of claim 62, wherein said enzymatic nucleic acid molecule is a DNAzyme.

73. (Previously presented) The method of claim 61, wherein said nucleic acid molecule comprises between 12 and 100 bases complementary to RNA of a CLCA1 gene.

Response to Restriction Requirement

Attorney Docket R0127B-REG

74. (Previously presented) The method of claim 62, wherein said nucleic acid molecule comprises between 12 and 100 bases complementary to RNA of a CLCA1 gene.

75. (Previously presented) The method of claim 61, wherein said nucleic acid molecule comprises between 14 and 24 bases complementary to RNA of a CLCA1 gene.

76. (Previously presented) The method of claim 62, wherein said nucleic acid molecule comprises between 14 and 24 bases complementary to RNA of a CLCA1 gene.